Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?-Reference-Cited by-同舟云学术

Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Published:2016 Issue:6 Volume:1 Page:esmoopen-2016-000125
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Grössmann Nicole,Wild Claudia

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Actual costs of cancer drugs in 15 European countries;van Harten;Lancet Oncol,2016

2. Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture;Fojo;JAMA Otolaryngol Head Neck Surg,2014

3. Why do cancer drugs get such an easy ride?;Light;BMJ,2015

4. A new anti-cancer drug in the market: good news for investors or for patients?;Apolone;Eur J Cancer,2008

5. The European medicines agency is still too close to industry;Garattini;BMJ,2016

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence;Health Policy;2022-02

2. Potential negative impact of reputed regulators’ decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis;PLOS ONE;2021-07-13

3. Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis;Pharmacology Research & Perspectives;2021-07-07

4. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time;European Journal of Cancer;2021-06

5. Assessing the pricing and benefits of oncology products: an update;Expert Review of Pharmacoeconomics & Outcomes Research;2021-05-04